anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Myocardial infarction (MI)-induced impaired cardiomyocyte (CM) mitochondrial function and microenvironmental inflammatory cascades severely accelerate the progression of heart failure for compromised myocardial repair. Modulation of the crosstalk between CM mitochondrial DNA (mtDNA) and STING has been recently identified as a robust strategy in enhancing MI treatment, but remains seldom explored. To develop a novel approach that can address persistent myocardial injury using this crosstalk, we report herein construction of a biomimetic hydrogel system, Rb1/PDA-hydrogel comprised of ginsenoside Rb1/polydopamine nanoparticles (Rb1/PDA NPs)-loaded carboxylated chitosan, 4-arm-PEG-phenylboronic acid (4-arm-PEG-PBA), and 4-arm-PEG-dopamine (4-arm-PEG-DA) crosslinked networks. An optimized hydrogel formulation presents not only desired adhesion properties to the surface of the myocardium, but also adaptability for deep myocardial injection, resulting in ROS scavenging, CM mitochondrial function protection, M1 macrophage polarization inhibition through the STING pathway, and angiogenesis promotion via an internal-external spatial combination. The enhanced therapeutic efficiency is supported by the histological analysis of the infarcted area, which shows that the fibrotic area of the MI rats decreases from 58.4% to 5.5%, the thickness of the left ventricular wall increases by 1-fold, and almost complete recovery of cardiac function after 28 days of treatment. Overall, this study reported the first use of a strong adhesive and injectable hydrogel with mtDNA and STING signaling characteristics for enhanced MI treatment via an internal-external spatial combination strategy.
Total cholesterol levels and other lipids are associated with violence in psychiatric patients. There is a paucity of studies on preventive interventions. In this study, an integrated multimodal lifestyle intervention (MLifeI) for management of repetitive violence in schizophrenia is proposed. A controlled clinical trial was carried out to evaluate the effects of MLifeI on management of repetitive violence through regulation of serum lipids, TC in particular, to the recommended levels in schizophrenia. The investigators examined whether the MLifeI could: 1. regulate or balance lipid profiles; 2. reduce violence risk; 3. improve impulsivity; and 4. improve general cognitive functioning. The multimodal lifestyle intervention included psychoeducation, lifestyle modification and health promotion and exercise. Outcome measures comprised lipid profiles, body mass index and violence-related parameters.
The present invention discloses a formula for nodule type acute mastitis and a preparation method. The formula, by mass, comprises 15 gram of trichosanthes kirilowii, 10 gram of nardostachyos root and rhizome, 10 gram of radix bupleuri, 15 gram of vinegar cyperus rotundus L, 30 gram of radix paeoniae alba, 10 gram of ligusticum wallichii, 10 gram of bitter orange, 10 gram of ginger-prepared pinellia, 12 gram of Chinese garlic, 30 gram of dandelion, 20 gram of cordate houttuynia, and 10 gram of prunella vulgaris. The preparation method comprises the following steps: weighing authentic Chinese herbal medicines according to the formula; only placing ginger-prepared pinellia in one place; soaking the Chinese herbal medicines; decocting the Chinese herbal medicines twice; mixing the two liquids; taking the liquid orally. The effective components of the herbal medicines of the formula for treating nodule type acute mastitis are complementary, may strengthen effects of dissipating binds and removing carbuncle, mildly regulating cold and heat, and mainly clearing away the fire. The formula is reasonable, fit for nodule type acute mastitis patient, especially for female yang-deficiency constitution after delivery. The preparation method is simple and convenient. The Chinese medicinal formula has quick result, definite curative effect. The improvement rate is 100%. The cure rate achieves 95%. The Chinese medicinal formula effectively relieves the pain of patients.
The invention discloses a fusion peptide, wherein the amino acid sequence of the fusion peptide is shown as SEQ ID No. 1 or 2. Also disclosed is an isolated polynucleotide encoding the aforementioned fusion peptide. Also disclosed is a DC vaccine for CTP-mediated induction of a CML cellular immune response, obtained by co-incubating the aforementioned fusion peptide with mature dendritic cells. Also discloses a preparation method of the vaccine, which comprises the following steps: 1) synthesizing the fusion peptide sequence; 2) culturing mature dendritic cells; 3) and co-incubating and washing the fusion peptide and the mature dendritic cells to obtain the DC vaccine. After a mouse is immunized by the dendritic cell vaccine, specific cellular immune response in the mouse is stimulated, cytotoxic T lymphocytes are induced and generated, and a slow granular cell line BaF3-P210 is killed, so that the feasibility of CTP mediated formation of DC vaccine and DC vaccine induced immune efficacy is proved.
Recent evidence suggests that deaf children with CIs exposed to nonnative sign language from hearing parents can attain age-appropriate vocabularies in both sign and spoken language. It remains to be explored whether deaf children with CIs who are exposed to early nonnative sign language, but only up to implantation, also benefit from this input and whether these benefits also extend to memory abilities, which are strongly linked to language development. The present study examined the impact of deaf children's early short-term exposure to nonnative sign input on their spoken language and their phonological memory abilities. Deaf children who had been exposed to nonnative sign input before and after cochlear implantation were compared to deaf children who never had any exposure to sign input as well as to children with typical hearing. The children were between 5;1 and 7;1 years of age at the time of testing and were matched on age, sex, and socioeconomic status. The results suggest that even short-term exposure to nonnative sign input has positive effects on general language and phonological memory abilities as well as on nonverbal working memory-with total length of exposure to sign input being the best predictor of deaf children's performance on these measures. The present data suggest that even access to early short-term nonnative visual language input is beneficial for the language and phonological memory abilities of deaf children with cochlear implants, suggesting also that parents should not be discouraged from learning and exposing their child to sign language. RESEARCH HIGHLIGHTS: This is the first study to examine the effects of early short-term exposure to nonnative sign input on French-speaking children with cochlear implants' spoken language and memory abilities. Early short-term nonnative exposure to sign input can have positive consequences for the language and phonological memory abilities of deaf children with CIs. Extended exposure to sign input has some additional and important benefits, allowing children to perform on par with children with typical hearing.
The invention discloses a making method of nanometer slow-release agent to simplify animal FSH superovulation in the embryo engineering technical domain, which comprises the following steps: 1) dissolving 0. 5%-3% fatty acid in the alkaline condition for 8-12h to make vesicle; 2) adjusting the grain size of vesicle and surface load; adding cationic surfactant in the vesicle liquid with weight rate of vesicle liquid and cationic surfactant at 1: 0. 05-0. 1; 3) adopting phosphoric acid buffer to adjust the grain size and surface load into 0. 05%-1. 5% vesicle slow-release agent. The invention simplifies the operation of superovulation without special request for instrument, which has strong repeatability.
Glomerular disease is a leading cause of CKD and ESKD. Although diabetic kidney disease is the most common cause of glomerular disease, nondiabetic causes include malignancy, systemic autoimmune conditions, drug effects, or genetic conditions. Nondiabetic glomerular diseases are rare diseases, with a paucity of high-quality clinical trials in this area. Furthermore, late referral can result in poor patient outcomes. This article reviews the current management of nondiabetic glomerular disease and explores the latest developments in drug treatment in this area. Current treatment of nondiabetic glomerular disease aims to manage complications (edema, hypertension, proteinuria, hyperlipidemia, hypercoagulability, and thrombosis) as well as target the underlying cause of glomerular disease. Treatment options include renin-angiotensin-aldosterone system inhibitors, statins/nonstatin alternatives, loop diuretics, anticoagulation agents, immunosuppressives, and lifestyle and dietary modifications. Effective treatment of nondiabetic glomerular disease is limited by heterogeneity and a lack of understanding of the disease pathogenesis. Sodium-glucose cotransporter-2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs, such as finerenone), with their broad anti-inflammatory and antifibrotic effects, have emerged as valuable therapeutic options for a range of cardiorenal conditions, including CKD. ns-MRAs are an evolving drug class of particular interest for the future treatment of nondiabetic glomerular disease, and there is evidence that these agents may improve kidney prognosis in various subgroups of patients with CKD. The benefits offered by ns-MRAs may present an opportunity to reduce the progression of CKD from a spectrum of glomerular disease. Several novel ns-MRA are in clinical development for both diabetic and nondiabetic CKD.
Forty patients with chronic consciousness disorder who met the inclusion criteria were recruited with the informed consent of the family. All the participants were randomized to receive "active" or "sham" treatment protocol. Stimulation was performed using a alternating stimulator linked to one anodal electrode and four cathodal electrodes. The anodal electrode was placed over the left dorsolateral prefrontal cortex (DLPFC; F3 in the 10-20 international system of EEG placement), and the four cathodal electrodes (AFz, FCz, F7, and C5 in the 10-20 international system EEG placement) were placed around the anodal electrode to form a current loop. Twenty 2 milliampere (mA) sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes per session, twice daily over 10 consecutive days, and the stimulus frequency was set as 6 Hertz (Hz). Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds. Before and after the tACS treatment, the state of consciousness was assessed according to coma recovery scale-revised(CRS-R), and19-channel EEG data were collected.
Purified water is obtained from tap water. NaCl is added to the purified water so that the conductivity thereof is at least 100 muS/cm. Then, electrolysis is applied. The obtained cathode water is output and neutralized. The obtained cathode water includes dissolved hydrogen (H<+>, H., H2) of at least 0.1 ppm. This dissolved hydrogen prevents or suppresses DNA damage.
BACKGROUND: While preoperative psychological distress is known to predict risk for worse total knee arthroplasty (TKA) outcomes, distress may be too broad and nonspecific a predictor in isolation. We tested whether there are distinct preoperative TKA patient types based jointly on psychological status and measures of altered pain processing that predict adverse clinical outcomes.
METHODS: In 112 TKA patients, we preoperatively assessed psychological status (depression, anxiety, and catastrophizing) and altered pain processing via a simple quantitative sensory testing protocol capturing peripheral and central pain sensitization. Outcomes (pain, function, opioid use) were prospectively evaluated at 6 weeks and 6 months after TKA. Cluster analyses were used to empirically identify TKA patient subgroups.
RESULTS: There were 3 distinct preoperative TKA patient subgroups identified from the cluster analysis. A low-risk (LR) group was characterized by low psychological distress and low peripheral and central sensitization. In addition, 2 subgroups with similarly elevated preoperative psychological distress were identified, differing by pain processing alterations observed: high-risk centralized pain and high-risk peripheral pain. Relative to LR patients, high-risk centralized pain patients displayed significantly worse function and greater opioid use at 6 months after TKA (P values <.05). The LR and high-risk peripheral pain patient subgroups had similar 6-month outcomes (P values >.05).
CONCLUSIONS: Among patients who have psychological comorbidity, only patients who have central sensitization were at elevated risk for poor functional outcomes and increased opioid use. Central sensitization may be the missing link between psychological comorbidity and poor TKA clinical outcomes. Preoperative testing for central sensitization may have clinical utility for improving risk stratification in TKA patients who have psychosocial risk factors.
Lf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with lactoferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
A double blinded randomized cross-over acute meal study will be carried out in which 15 healthy male participants will attend two study visits, separated by at least one week. On each study visit, fasted participants will consume either the solid or the liquid emulsion, in a randomized order. Both emulsions tested will have the exact same composition only differing in the physical state of the lipid emulsions, in order to isolate the impact of physical state, specifically, on metabolic response. Postprandial lipemia and satiety will be measured for 6 hours after consumption of the test beverage. The study meals will include crushed acetominophen, the appearance of which will be measured in plasma as a measure of liquid content gastric emptying. Participants will be asked to maintain their usual lifestyle habits throughout the study, with some changes in the 48 hour period leading up to each of the two visits.
PURPOSE:A gelatinous pharmaceutical for surgical use, prepared by formulating ''Diclofenac Sodium'' which is an active constituent with a specific medium, a carboxyvinyl polymer which is a gelling agent and a weakly basic substance which is a neutralizing agent, useful as an anti-inflammatory and analgesic agent, and having improved stability and feeling of use. CONSTITUTION:A gelatinous pharmaceutical for surgical use prepared by formulating ''Diclofenac Sodium'' of the formula with water, a lower alkanol or a glycol as a medium, a carboxyvinyl polymer as a gelling agent and a weakly basic substance as a neutralizing agent. The content of the compound expressed by the formula is preferably 0.5-2wt%. A combination of water, lower alkanol, e.g. ethanol or isopropanol, glycol, e.g. propylene glycol or 1,3-butylene glycol is required for the medium. An aliphatic amine is preferred for the weakly basic substance. The pharmaceutical has improved anti-inflammatory and analgesic effects by the percutaneous absorption and further improved stability and feeling of use.
Cancer chemotherapy induces cell stress in rapidly dividing cancer cells to trigger their growth arrest and apoptosis. However, adverse effects related to cardiotoxicity underpinned by a limited regenerative potential of the heart limits clinical application: In particular, chemotherapy with doxorubicin (DOXO) causes acute heart injury that can transition to persisting cardiomyopathy (DOXO-CM). Here, we tested if MuRF1 inhibition ("MuRFi") was able to attenuate DOXO-CM. To mimic DOXO chemotherapy, we treated mice over four weeks with five DOXO injections, resulting in a cumulative dosage of 25 mg/kg. At day 28, mice had lower body and heart weights, reduced cardiac cross-sectional myofibrillar areas (CSAs), and disturbed functional ejection fractions (EFs) and fractional shortenings (FS) as indicated by echocardiography (ECHO). In contrast, mice with a 1 g/kg Myomed#205 spiked diet, a previously described experimental MuRFi therapy, showed lower DOXO-CM at day 28, and also reduced acute DOXO cardiac injury at day 7 (single DOXO dose; 15 mg/kg). Underlying molecular signatures using Western blot (WB) assays showed at day 28 reduced phospho-AKT (AKTp) and phospo-4EBP1 (4 EBP1p) levels following DOXO that were normalized following MuRFi treatment. Taken together, our data suggest that MuRFi treatment is suitable to attenuate DOXO-CM by preserving AKTp and 4 EBP1p levels in DOXO stressed cardiomyocytes, thereby supporting de novo protein translation and cardiomyocyte survival under translational arrest stress.
PURPOSE:To obtain a water-soluble preservative having excellent stability and giving a transparent and stable solution only by adding to a liquid object, etc., and lightly stirring the mixture, by dissolving a p-hydroxybenzoic acid ester and quillaja saponin in a hydrated hydrophilic organic solvent. CONSTITUTION:A p-hydroxybenzoic acid ester having excellent preservative and fungicidal effect and high safety, especially butyl ester, etc. is used as an active component, and is compound with a solubilizing agent consisting of a quillaja saponin which is a natural surfactant used in food industry. The composition is dissolved in a hydrophilic organic solvent such as hydrated ethyl alcohol, acetic acid, etc., stirred under heating until the whole mixture turns transparent, and cooled to obtain the objective preservative. EFFECT:There is no lowering of the commercial value of the preservative caused by the isolation of p-hydroxybenzoic acid. The quillaja saponin is tasteless and odorless at the normal dose, and is inert to the taste and flavor of the food and drink to be treated. The solubilization effect is maintained even in acidic state. The agent can be used in foods, drinks, cosmetics, pharmaceuticals, etc. without troubles.
Cases of renal failure (including acute renal failure), some with a fatal outcome, have occurred in patients taking everolimus tablets. Elevations of serum creatinine and proteinuria have been reported in patients taking everolimus [see Adverse Reactions (6.1)]. The incidence of Grade 3 and 4 elevations of serum creatinine was up to 2% and up to 1%, respectively. The incidence of Grade 3 and 4 proteinuria was up to 1% and up to 0.5%, respectively. Monitor renal function prior to starting everolimus and annually thereafter. Monitor renal function at least every 6 months in patients who have additional risk factors for renal failure.
Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
PROBLEM TO BE SOLVED: To obtain the subject enhancer having excellent neurotrophin action enhancing activity and useful as a medicine for neurodegeneration diseases by including a specified phenanthridinone derivative. SOLUTION: This enhancer is obtained by including 6(5H)-phenanthridinone derivative of formula I (R1 and R2 are each H or a halogen; R3 is amino) [e.g. 1-amino-3,8-dichloro-6(5H)-phenanthridinone]. The compound of formula I is obtained by e.g. reacting a compound of formula II with nitric acid in acetic acid to obtain a compound of formula III and reducing the resultant in an inactive solvent in the presence of formic acid using palladium carbon. As medicines for neurodegeneration diseases, prophylactic and therapeutic agents for Alzheimer type demantia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's chorea and peripheral sensory neuropathy and inhibitors for neuron death and therapeutic agents for sequelae after cerebral ischemia can be listed.
AIMS: We conducted a systematic review of post-test communication protocols and observational studies regarding counseling for a positive sexually transmitted infection (STI) result and also discuss the role of dental specialist (e.g., oral medicine) in this sense.
METHODS AND RESULTS: The search process followed the parameters of PRISMA 2020 guidelines. MEDLINE/PubMed, Web of Science, Scopus, EMBASE, and LILACS were consulted with a specific search strategy for each one. Additionally, the references of the included studies, grey literature, and experts were consulted. Four protocols and 18 observational studies were included in this systematic review, published between 1997 and 2022 in the Americas and Europe. The communication protocols emphasized the importance of conducting personal and private discussions with patients to address their fears and questions. Among the observational studies, 56% indicated that post-test counseling was either ineffective or absent. Furthermore, 22% of the studies used telephone communication to deliver results to patients.
CONCLUSIONS: Our study showed that the communication process of a positive STI result affects the patients in several aspects, as treatment adherence and their relationship with the community. Nevertheless, this process of STI post-test communication seems to be flawed, which brings potential negative effects to patients.
Icatibant Injection is supplied as a single-dose, prefilled syringe for subcutaneous administration. Each syringe delivers 3 mL of a sterile solution of icatibant 30 mg (as icatibant acetate). The solution is clear and colorless. Each glass syringe has a bromobutyl plunger stopper, which is not made with natural rubber latex.

Icatibant Injection is available in cartons containing one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 24201-207-01.

Icatibant Injection is also available in a pack containing 3 cartons; each carton contains one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 24201-207-03.